Genmab | GEN - Cash And Equivalent

Stock Price
2,007.00
Daily Change
-90.00 -4.29%
Monthly
-0.15%
Yearly
43.10%
Q1 Forecast
1,920.90

Genmab reported DKK1.3B in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Agios Pharmaceuticals USD 92.71M 11.84M Sep/2025
Amarin USD 122.8M 25.08M Sep/2025
Amgen USD 9.13B 316M Dec/2025
argenx SE USD 4.3B 2.21B Sep/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Bayer EUR 5.9B 1.34B Sep/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Demant DKK 1.14B 30M Jun/2025
Exelixis USD 376.3M 211.87M Sep/2025
Fresenius Medical Care EUR 1.26B 459.13M Sep/2025
Galapagos EUR 64.46M 43.61M Sep/2025
Genmab DKK 1.3B 323M Jun/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
GN Store Nord DKK 767M 363M Sep/2025
GRIFOLS EUR 558.69M 194.13M Jun/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
Insmed USD 334.76M 949.56M Sep/2025
Lonza CHF 1.11B 286M Dec/2024
Merck EUR 1.17B 161M Jun/2025
Novartis USD 9.56B 2.9B Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
UCB EUR 1.57B 1.14B Dec/2024